BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data
25/5 16:53
Black Diamond Therapeutics shares sink as phase II silevertinib data show NSCLC efficacy and CNS activity, but raise investor concerns on the early nature of the dataset....
|
|
|
25/5 16:53
Black Diamond Therapeutics shares sink as phase II silevertinib data show NSCLC efficacy and CNS activity, but raise investor concerns on the early nature of the dataset....